Regorafenib dose escalation versus fixed dosing in refractory metastatic colorectal cancer: Survival outcomes from a sub-analysis of the ReTrITA study.

Journal of Clinical Oncology 2026

View at publisher
Authors: Carlo Signorelli, Michele Basso, Maria Alessandra Calegari, Alessandro Passardi, Chiara Gallio, Jessica Lucchetti, Ina Valeria Zurlo, Emanuela Dell’Aquila, Donatello Gemma, Alessandra Emiliani, Giulia Arrivi, Federica Zoratto
+8 more Maria Grazia Morandi, Fiorenza Santamaria, Manuela Dettori, Antonella Cosimati, Rosa Saltarelli, Alessandro Minelli, Emanuela Lucci Cordisco, Mario Giovanni Chilelli
DOI: 10.1200/jco.2026.44.2_suppl.136
Cited by: 0

Abstract

136 Background: The ReTrITA study is a large, multicenter retrospective analysis evaluating real-world outcomes of regorafenib (R) and trifluridine/tipiracil (T) in refractory metastatic colorectal cancer (mCRC) across 17 Italian centers (2012–2023). This prespecified subgroup analysis focused on the impact of different initial regorafenib dosing strategies on survival outcomes. Methods: Patients treated with regorafenib (n = 713) were stratified into three groups according to starting dose: ReDOS stepwise escalation (n = 313), fixed reduced dose

Fields of Study & Subjects

Colorectal Cancer Treatments and Studies Colorectal Cancer Surgical Treatments Intraperitoneal and Appendiceal Malignancies

Publication details

Journal / source
Journal of Clinical Oncology
Volume
44
Issue
2_suppl
Pages
136–136
Publication date
10 January 2026
Language
EN